Recent systematic reviews and meta-analyses have demonstrated that SGLT2 inhibitors significantly increase hemoglobin and hematocrit levels in patients with type 2 diabetes and chronic kidney disease [8,9]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.